The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
2007

Belinostat Suppresses Bladder Cancer Growth

Sample size: 20 publication 10 minutes Evidence: moderate

Author Information

Author(s): Michael T Buckley, Joanne Yoon, Herman Yee, Luis Chiriboga, Leonard Liebes, Gulshan Ara, Xiaozhong Qian, Dean F Bajorin, Tung-Tien Sun, Xue-Ru Wu, Iman Osman

Primary Institution: New York University School of Medicine

Hypothesis

Does belinostat effectively inhibit bladder cancer cell growth in vitro and in vivo?

Conclusion

Belinostat inhibits bladder cancer and supports its clinical evaluation for treating superficial bladder cancer.

Supporting Evidence

  • Belinostat caused a significant dose-dependent growth inhibition in all tested bladder cancer cell lines.
  • The 5637 cell line was the most sensitive to belinostat treatment.
  • Belinostat-treated mice showed less bladder weight and no hematuria compared to control mice.
  • IHC analysis indicated increased expression of p21WAF1 in belinostat-treated mice.

Takeaway

Belinostat is a medicine that helps stop bladder cancer from growing in mice and might help people with bladder cancer too.

Methodology

The study assessed the effects of belinostat on bladder cancer cell lines and a transgenic mouse model, measuring growth inhibition and cell cycle distribution.

Limitations

The study primarily used a transgenic mouse model, which may not fully replicate human bladder cancer.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1479-5876-5-49

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication